Business
HLS Therapeutics Licenses and Files 'Athelas One' Point-of-Care Device
HLS Therapeutics Licenses and Files 'Athelas One' Point-of-Care Device Canada News...
About this update from Hls Therapeutics, Inc.
[{"type":"text","content":"\n\n\n\nHLS Therapeutics Licenses and Files 'Athelas One' Point-of-Care Device\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nTORONTO, March 14, 2019\n\n\n\nFrom a single drop of blood from the tip of a finger, the point-of-care technology generates white blood cell counts and neutrophils numbers in minutes When approved in Canada, the Athelas One technology could help lower the most commonly cited barrier for using clozapine among those who could benefit from it Upon its approval, the technology will become part of the Clozaril Support and Assistance Network (CSAN®) and made available to Canadian Institutions and HCPs under the name CSAN® ProntoTM TORONTO, March 14, 2019 /CNW/ - HLS Therapeutics Inc. (\"HLS\" or the \"Company\") (TSX: HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular markets, announces that it has in-licensed the exclusive Canadian rights for the Athelas One device. The Athelas One is an FDA-cleared capillary point-of-care medical device that is designed to help enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed CLOZARIL® (clozapine), the only class of medication approved for Treatment Resistant Schizophrenia (\"TRS\"). HLS has the exclusive rights to the device in the field of schizophrenia.\nFollowing its filing in January, the device was accepted for review by Health Canada on March 13th.  Conditional on its approval in Canada, HLS will introduce the device as part of the current Clozaril Support and Assistance Network (CSAN®) under the name, \"CSAN® ProntoTM\".\nIt is estimated that schizophrenia affects 1% of the population, or approximately 370,000 Canadians, and 25-30% of patients with schizophrenia (approximately 111,000) meet the criteria for TRS.1,2 TRS patients are those that are suffering with schizophrenia and are found to be non-responsive to, or intolerant of, conventional antipsychotic medications. For these patients, the only treatment that is approved and recommended by Canadian Psychi...